Physician profile
Miles E Gresham
NPI 1548203680
$6,199.36
in general payments reported to CMS, 2019-2025
31 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $269 · 2021: $949 · 2022: $861 · 2023: $712 · 2024: $1,271 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Education: $34.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.04 |
| Education | $34.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,452.36 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Abbvie INC. | $1,342.70 | 2019-2025 | |
| Janssen Biotech, INC. | $819.52 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $367.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $361.92 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $356.64 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $169.66 | 2024-2025 | Voquezna |
| Celgene Corporation | $138.61 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $123.74 | 2021-2024 | Linzess |
| Genzyme Corporation | $101.09 | 2022-2024 | |
| Qol Medical, LLC | $98.95 | 2019-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $96.67 | 2024-2025 | Vegzelma, Zymfentra |
| Mallinckrodt Hospital Products INC. | $90.39 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $86.71 | 2024-2025 | Iqirvo |
| Ucb, INC. | $70.94 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $70.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $60.91 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $53.08 | 2019-2020 | |
| Amgen INC. | $39.14 | 2025 | Uplizna |
| Romark Laboratories, Lc | $35.36 | 2019-2020 | |
| Daiichi Sankyo INC. | $32.53 | 2019 | |
| Redhill Biopharma INC. | $30.87 | 2020-2021 | |
| Braintree Laboratories, INC. | $28.87 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $28.70 | 2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $27.68 | 2023-2024 | Ocaliva |
| Orphalan INC | $24.74 | 2024 | Cuvrior |
| Nestle Healthcare Nutrition INC. | $24.37 | 2021-2022 | |
| Evoke Pharma, INC. | $19.87 | 2024 | |
| Axonics, INC. | $16.56 | 2024 | Axonics |
| Shire North American Group INC | $14.34 | 2019 | |
| Merck Sharp & Dohme LLC | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Gresham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.